ArticleClinical sarcoma research2012
Sarcomas in hereditary retinoblastoma.
Article in Clinical sarcoma research, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 71 citations in OpenAlex.
- Extraskeletal osteosarcoma arising in the globe of an irradiated, heritable retinoblastoma survivor.American journal of ophthalmology case reports · 2026Article
- Unraveling syndrome-driven osteosarcoma: genetic insights and therapeutic frontiers.Orphanet journal of rare diseases · 2026Review
- Genetically Modified Mouse Models for Sarcoma Research: A Comprehensive Review.Current oncology reports · 2025Review
- Article
- Targeted therapies in retinoblastoma: GD2-directed immunotherapy following autologous stem cell transplantation and evaluation of alternative target B7-H3.Cancer immunology, immunotherapy : CII · 2024Article
- Multi-Anticancer Activities of Phytoestrogens in Human Osteosarcoma.International journal of molecular sciences · 2023Review
- Surgical resection of retinoblastoma-associated bladder leiomyosarcoma during pregnancy: a case report.BMC urology · 2023Article
- Review
- Subacute dyspepsia: a curious presentation of an ominous pathology.Clinical medicine (London, England) · 2022Article
- Retroperitoneal Sarcoma Care in 2021.Cancers · 2022Review
- Correlative Study on the Relationship between the Expression of m6a-Related Genes and the Prognosis and Immunotherapy of Soft Tissue Sarcoma.BioMed research international · 2022Article
- Identification of Epigenetically Modified Hub Genes and Altered Pathways Associated With Retinoblastoma.Frontiers in cell and developmental biology · 2022Article
- Soft Tissue Sarcoma: An Insight on Biomarkers at Molecular, Metabolic and Cellular Level.Cancers · 2021Review
- Benign Tumors in Long-Term Survivors of Retinoblastoma.Cancers · 2021Article
- NovelDiagnostics (Basel, Switzerland) · 2020Article
- Recommendations for Long-Term Follow-up of Adults with Heritable Retinoblastoma.Ophthalmology · 2020Review
- Molecular Biology of Osteosarcoma.Cancers · 2020Review
- Clear cell sarcoma of the esophagus: A rare location.Clinical case reports · 2020Article
- Eag1 Gene and Protein Expression in Human Retinoblastoma Tumors and its Regulation by pRb in HeLa Cells.Genes · 2020Article
- Bone and Soft-Tissue Sarcoma Risk in Long-Term Survivors of Hereditary Retinoblastoma Treated With Radiation.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Children diagnosed with the hereditary form of retinoblastoma (Rb), a rare eye cancer caused by a germline mutation in the RB1 tumor suppressor gene, have excellent survival, but face an increased risk of bone and soft tissue sarcomas. This predisposition to sarcomas has been attributed to genetic susceptibility due to inactivation of the RB1 gene as well as past radiotherapy for Rb. The majority of bone and soft tissue sarcomas among hereditary Rb survivors occur in the head, within the radiation field, but they also occur outside the radiation field. Sarcomas account for almost half of the second primary cancers in hereditary Rb survivors, but they are very rare following non-hereditary Rb. Sarcomas among hereditary Rb survivors arise at ages similar to the pattern of occurrence in the general population. There has been a trend over the past two decades to replace radiotherapy with chemotherapy and other focal therapies (laser or cryosurgery), and most recently, chemosurgery in order to reduce the incidence of sarcomas and other second cancers in Rb survivors. Given the excellent survival of most Rb patients treated in the past, it is important for survivors, their families and health care providers to be aware of the heightened risk for sarcomas in hereditary patients.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.